FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024872389> ?p ?o ?g. }

• W2024872389 abstract "You have accessJournal of UrologyProstate Cancer: Basic Research II1 Apr 20121320 ALTERED EXPRESSION OF FARNESYL PYROPHOSPHATE SYNTHASE IN PROSTATE CANCER – EVIDENCE FOR A ROLE OF THE MEVALONATE PATHWAY FOR DISEASE PROGRESSION Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Stefan Aufderklamm, Valentina Gerber, Ulrich Vogel, Arnulf Stenzl, and Christian Schwentner Tilman TodenhöferTilman Todenhöfer Tübingen, Germany More articles by this author , Jörg HennenlotterJörg Hennenlotter Tübingen, Germany More articles by this author , Ursula KühsUrsula Kühs Tübingen, Germany More articles by this author , Stefan AufderklammStefan Aufderklamm Tübingen, Germany More articles by this author , Valentina GerberValentina Gerber Tübingen, Germany More articles by this author , Ulrich VogelUlrich Vogel Tübingen, Germany More articles by this author , Arnulf StenzlArnulf Stenzl Tübingen, Germany More articles by this author , and Christian SchwentnerChristian Schwentner Tübingen, Germany More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.1667AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Preclinical studies demonstrated direct and indirect effects of drugs inhibiting the mevalonate pathway, such as nitrogen-containing bisphosphonates (NBPs) and statins, on tumor growth and cancer progression. However, the exact role of this pathway in prostate cancer (PC) progression has not been identified yet. Aim of the study was to evaluate the expression of the enzyme farnesyl pyrophosphate synthase (FPPS), the molecular target of NBPs and key enzyme of the mevalonate pathway, in PC tissue. METHODS PC and corresponding benign prostatic tissue samples of 114 consecutive men who underwent radical prostatectomy were constructed to a tissue microarray (median Age 65, median PSA 9 ng/ml, median Gleason 6). FPPS staining was performed using a polyclonal antibody and expression was quantified by the Remmele/Stegner immunoreactivity score (IRS) including both percentage of positive cells and staining intensity (1-12). Patients' clinical follow-up was assessed with a median follow-up of 69 months. IRS was correlated to pathological and clinical data by Wilcoxon-Kruskall-Wallis tests and linear regression analysis. Impact of FPPS expression on clinical course was assessed univariate by the Kaplan Meier method and multivariate by Cox proportional hazard analysis. RESULTS Mean IRS for FPPS in PC and benign tissue areas were 5.7 (95% CI 5.0-6.5) and 2.6 (2.1-3.0, p<0.0001). In PC tissue of patients with locally advanced disease (pT≥3), mean IRS were 6.87 (5.57-8.17) vs. 5.09 (4.22-5.96) in patients with organ-confined disease (p=0.035). IRS of PC tissue significantly correlated with Gleason score (p=0.007). No significant correlation was observed between preoperative PSA and FPPS expression of PC tissue (p=0.13). Patients with moderate or strong FPPS expression (IRS>3) in tumor areas had a lower biochemical recurrence-free survival compared to the low/no expression group (p=0.01). No significant correlation was observed between FPPS expression and cancer-specific or metastasis free survival. CONCLUSIONS This is the first study investigating the expression of FPPS in PC specimens. The association of FPPS with established histopathological risk parameters indicates a potential contribution of the mevalonate pathway to the progression of PC. Inhibition of this pathway in PC patients might have an effect on tumor progression beyond inhibition of PC-related bone disease. Moreover, FPPS expression might be a prognostic indicator for potential antitumor effects of mevalonate pathway-inhibiting drugs. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e535 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Tilman Todenhöfer Tübingen, Germany More articles by this author Jörg Hennenlotter Tübingen, Germany More articles by this author Ursula Kühs Tübingen, Germany More articles by this author Stefan Aufderklamm Tübingen, Germany More articles by this author Valentina Gerber Tübingen, Germany More articles by this author Ulrich Vogel Tübingen, Germany More articles by this author Arnulf Stenzl Tübingen, Germany More articles by this author Christian Schwentner Tübingen, Germany More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2024872389 created "2016-06-24" @default.
• W2024872389 creator A5034310234 @default.
• W2024872389 creator A5041772630 @default.
• W2024872389 creator A5052233372 @default.
• W2024872389 creator A5053760424 @default.
• W2024872389 creator A5067369608 @default.
• W2024872389 creator A5072818969 @default.
• W2024872389 creator A5086583298 @default.
• W2024872389 creator A5090616738 @default.
• W2024872389 date "2012-04-01" @default.
• W2024872389 modified "2023-10-11" @default.
• W2024872389 title "1320 ALTERED EXPRESSION OF FARNESYL PYROPHOSPHATE SYNTHASE IN PROSTATE CANCER – EVIDENCE FOR A ROLE OF THE MEVALONATE PATHWAY FOR DISEASE PROGRESSION" @default.
• W2024872389 cites W143610572 @default.
• W2024872389 cites W1533495843 @default.
• W2024872389 cites W1867790738 @default.
• W2024872389 cites W1977915186 @default.
• W2024872389 cites W1978478799 @default.
• W2024872389 cites W1982855449 @default.
• W2024872389 cites W1983701258 @default.
• W2024872389 cites W1984713765 @default.
• W2024872389 cites W1987510666 @default.
• W2024872389 cites W1989037332 @default.
• W2024872389 cites W1995231897 @default.
• W2024872389 cites W2019411105 @default.
• W2024872389 cites W2021852492 @default.
• W2024872389 cites W2031383041 @default.
• W2024872389 cites W2045031638 @default.
• W2024872389 cites W2084865918 @default.
• W2024872389 cites W2086003582 @default.
• W2024872389 cites W2089199139 @default.
• W2024872389 cites W2093164779 @default.
• W2024872389 cites W2095977821 @default.
• W2024872389 cites W2100237319 @default.
• W2024872389 cites W2119185578 @default.
• W2024872389 cites W2134708296 @default.
• W2024872389 cites W2148096512 @default.
• W2024872389 cites W2160560649 @default.
• W2024872389 cites W2162889992 @default.
• W2024872389 cites W2165799265 @default.
• W2024872389 cites W2171711077 @default.
• W2024872389 cites W2340386540 @default.
• W2024872389 cites W4205145397 @default.
• W2024872389 doi "https://doi.org/10.1016/j.juro.2012.02.1667" @default.
• W2024872389 hasPublicationYear "2012" @default.
• W2024872389 type Work @default.
• W2024872389 sameAs 2024872389 @default.
• W2024872389 citedByCount "0" @default.
• W2024872389 crossrefType "journal-article" @default.
• W2024872389 hasAuthorship W2024872389A5034310234 @default.
• W2024872389 hasAuthorship W2024872389A5041772630 @default.
• W2024872389 hasAuthorship W2024872389A5052233372 @default.
• W2024872389 hasAuthorship W2024872389A5053760424 @default.
• W2024872389 hasAuthorship W2024872389A5067369608 @default.
• W2024872389 hasAuthorship W2024872389A5072818969 @default.
• W2024872389 hasAuthorship W2024872389A5086583298 @default.
• W2024872389 hasAuthorship W2024872389A5090616738 @default.
• W2024872389 hasConcept C112243037 @default.
• W2024872389 hasConcept C121608353 @default.
• W2024872389 hasConcept C126322002 @default.
• W2024872389 hasConcept C134651460 @default.
• W2024872389 hasConcept C181199279 @default.
• W2024872389 hasConcept C185592680 @default.
• W2024872389 hasConcept C2775933503 @default.
• W2024872389 hasConcept C2776043855 @default.
• W2024872389 hasConcept C2776990775 @default.
• W2024872389 hasConcept C2777654137 @default.
• W2024872389 hasConcept C2779134260 @default.
• W2024872389 hasConcept C2779982574 @default.
• W2024872389 hasConcept C2780192828 @default.
• W2024872389 hasConcept C502942594 @default.
• W2024872389 hasConcept C55493867 @default.
• W2024872389 hasConcept C71924100 @default.
• W2024872389 hasConceptScore W2024872389C112243037 @default.
• W2024872389 hasConceptScore W2024872389C121608353 @default.
• W2024872389 hasConceptScore W2024872389C126322002 @default.
• W2024872389 hasConceptScore W2024872389C134651460 @default.
• W2024872389 hasConceptScore W2024872389C181199279 @default.
• W2024872389 hasConceptScore W2024872389C185592680 @default.
• W2024872389 hasConceptScore W2024872389C2775933503 @default.
• W2024872389 hasConceptScore W2024872389C2776043855 @default.
• W2024872389 hasConceptScore W2024872389C2776990775 @default.
• W2024872389 hasConceptScore W2024872389C2777654137 @default.
• W2024872389 hasConceptScore W2024872389C2779134260 @default.
• W2024872389 hasConceptScore W2024872389C2779982574 @default.
• W2024872389 hasConceptScore W2024872389C2780192828 @default.
• W2024872389 hasConceptScore W2024872389C502942594 @default.
• W2024872389 hasConceptScore W2024872389C55493867 @default.
• W2024872389 hasConceptScore W2024872389C71924100 @default.
• W2024872389 hasIssue "4S" @default.
• W2024872389 hasLocation W20248723891 @default.
• W2024872389 hasOpenAccess W2024872389 @default.
• W2024872389 hasPrimaryLocation W20248723891 @default.
• W2024872389 hasRelatedWork W1970664317 @default.
• W2024872389 hasRelatedWork W1973023022 @default.
• W2024872389 hasRelatedWork W2024872389 @default.
• W2024872389 hasRelatedWork W2058275176 @default.
• W2024872389 hasRelatedWork W2072911080 @default.
• W2024872389 hasRelatedWork W2081950580 @default.
• W2024872389 hasRelatedWork W2165799265 @default.

• next